The PROSPLIGN project – PROSPecting natural LIGNin biodiversity towards unlocking value-added bioactive motifs and molecules – a European funded Research and Innovation Action project, officially kicked off in Dublin last week.  

The key project objective is to apply state-of-the-art methodologies to prospect the bioactivity potential of lignin – a natural, abundant and sustainable biopolymer component of lignocellulosic biomass. PROSPLIGN’s bioprospecting workflows will focus on the identification of compounds and validation of their potential for application in the pharmaceuticals, cosmetics and fragrances markets.  

Hosted by the consortium coordinator KelAda Pharmachem, the meeting brought together all the partners to discuss priorities and set in motion the project strategic actions. KelAda Pharmachem CEO, Brian Kelly notes, ‘’We are thrilled to start a project based on research and technology we have been developing over the last years. A big thank you to all the partners for the engagement, the fruitful discussions and the detailed elaboration on their research work. We are certain we found the right people for the job!’’. 

Four universities, two SMEs and a research institute from six different European countries form the project consortium. The partners include KelAda Pharmachem (Ireland), University of Helsinki (Finland), Fundación MEDINA (Spain), NOVA University Lisbon (Portugal), University College Dublin (Ireland), Magfi (Malta) and the Bern University of Applied Sciences (Switzerland). 

For more information, please contact: Zoi Volioti – PROSPLIGN media contact – zoivol@magfi.eu